Related Experiment Video

Updated: Jun 15, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Sunitinib for the management of advanced renal cell carcinoma

Bernard Escudier1

  • 1Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif, France. escudier@igr.fr

Expert Review of Anticancer Therapy
|March 11, 2010
PubMed

Insights

Sunitinib significantly improves progression-free survival in metastatic renal cell carcinoma (mRCC) compared to interferon-alpha. This targeted therapy is a recommended first-line treatment for mRCC, offering a manageable safety profile.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced and metastatic renal cell carcinoma (mRCC) management increasingly relies on targeted therapies.
  • Sunitinib, an oral multitargeted receptor tyrosine kinase inhibitor, has emerged as a key treatment option.

Purpose of the Study:

  • To review data supporting sunitinib's efficacy in mRCC.
  • To discuss optimal clinical management strategies for sunitinib in mRCC patients.

Main Methods:

  • Review of clinical trial data, including a Phase III trial comparing sunitinib to interferon-alpha.
  • Analysis of progression-free survival and adverse event profiles.

Main Results:

  • Sunitinib demonstrated a median progression-free survival of 11 months in previously untreated mRCC patients, more than double that of interferon-alpha (5 months).
  • Sunitinib is generally well-tolerated with a manageable adverse event profile.

Conclusions:

  • Sunitinib is a recommended first-line treatment for favorable or intermediate risk mRCC based on demonstrated efficacy.
  • Optimal management strategies are crucial for maximizing sunitinib's benefit in clinical practice.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...